Microtransponder-based multiplex assay for genotyping cystic fibrosis

Area of Science:

• Biotechnology
• Genetics
• Molecular Diagnostics

Background:

• Cystic Fibrosis (CF) is a genetic disorder.
• Accurate detection of CF mutations is crucial for diagnosis and management.
• Existing genotyping methods may have limitations in throughput or cost.

Purpose of the Study:

• To develop and evaluate a novel genotyping assay for detecting 50 cystic fibrosis (CF) mutations.
• To assess the performance of a microtransponder (MTP) based platform for CF genotyping.

Main Methods:

• Development of a multiplex assay utilizing microtransponder (MTP) technology.
• Amplification of 18 CF transmembrane regulator (CFTR) DNA fragments covering 50 mutations via multiplex PCR.
• Multiplex allele-specific primer extension (ASPE) reactions followed by hybridization to MTP-synthesized capture probes.
• Analysis using a custom automated fluorescence and radio frequency (RF) readout instrument.

Main Results:

• The assay was validated on 23 commercial DNA samples (internal study) and 32 DNA samples (external study).
• High accuracy was observed with correct call rates of 98.8% (internal) and 95.7% (external).
• Low false-positive (1.1% internal, 3.9% external) and false-negative (0.12% internal, 0.36% external) rates were reported.

Conclusions:

• The microtransponder (MTP)-based multiplex assay is a viable platform for cystic fibrosis (CF) genotyping.
• This technology offers a potentially efficient method for detecting multiple CF mutations.
• The assay demonstrates robust performance suitable for clinical applications.